NMR based metabolomics comparison of different blood sampling techniques in awake and anesthetized rats by Du, Hongying et al.
molecules
Article
NMR Based Metabolomics Comparison of Different
Blood Sampling Techniques in Awake and
Anesthetized Rats
Hongying Du 1,*,†, Shuang Li 2,†, Yingfeng Zhang 2,3, Huiling Guo 2, Liang Wu 2, Huili Liu 2,3,
Anne Manyande 4, Fuqiang Xu 2,3 and Jie Wang 2,3,*
1 College of Food Science and Technology, Huazhong Agricultural University, Wuhan 430070, China
2 Key Laboratory of Magnetic Resonance in Biological Systems, State Key Laboratory of Magnetic Resonance
and Atomic and Molecular Physics, Wuhan Institute of Physics and Mathematics, Chinese Academy of
Sciences, Wuhan 430071, China
3 University of Chinese Academy of Sciences, Beijing 100049, China
4 School of Human and Social Sciences, University of West London, Middlesex TW89GA, UK
* Correspondence: hydu@mail.hzau.edu.cn (H.D.); jie.wang@wipm.ac.cn (J.W.);
Tel.: +86-27-87288375 (H.D.); +86-27-87197653 (J.W.)
† Same contribution to the work.
Received: 14 June 2019; Accepted: 11 July 2019; Published: 12 July 2019


Abstract: The composition of body fluids has become one of the most commonly used methods for
diagnosing various diseases or monitoring the drug responses, especially in serum/plasma. It is
therefore vital for investigators to find an appropriate way to collect blood samples from laboratory
animals. This study compared blood samples collected from different sites using the NMR based
metabolomics approach. Blood samples were collected from the saphenous vein (awake state),
tail vein (awake and anesthetized states after administration of sevoflurane or pentobarbital) and
the inferior thoracic vena cava (ITVC, anesthetized state). These approaches from the saphenous
and tail veins have the potential to enable the collection of multiple samples, and the approach from
ITVC is the best method for the collection of blood for the terminate state. The compositions of small
molecules in the serum were determined using the 1H-NMR method, and the data were analyzed
with traditional correlation analysis, principle component analysis (PCA) and OPLS-DA methods.
The results showed that acute anesthesia significantly influenced the composition of serum in a very
short period, such as the significant increase in glucose, and decrease in lactate. This indicates that it
is better to obtain blood samples under the awake state. From the perspective of animal welfare and
multiple sampling, the current study shows that the saphenous vein and tail vein are the best locations
to collect multiple blood samples for a reduced risk of injury in the awake state. Furthermore, it is
also suitable for investigating pharmacokinetics and the effects of drug intervention on animals.
Keywords: blood collection; serum; NMR; metabolomics; saphenous vein
1. Introduction
For clinical applications, the composition of body fluids has become a commonly used standard
for diagnosing various diseases or monitoring of drug responses. There are several kinds of body
fluids, such as urine [1], blood plasma [2], serum [3], cerebrospinal fluid [4] etc. Among these samples,
blood/serum measurements are the cornerstone of clinical testing; thus, numerous investigations into
the analysis of blood serum composition exist.
Rodents are the most popular animal model for pre-clinical studies; hence, it is very important to
get blood samples as few animals as possible, and to improve data evaluation. Currently, there are
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many common sites for blood collection in rodents, such as the tail vein (easy for catheterization),
retro-orbital sinus, facial vein, saphenous vein, heart or the inferior thoracic vena cava (ITVC) [5,6].
For terminal stage studies, blood collection sites from the heart or ITVC are preferred, due to the
good quality volume of blood from animals. For the collection of multiple blood samples over a short
period of time, the approaches of retro-orbital sinus, tail vein, or saphenous vein are appropriate.
For the approach of retro-orbital sinus, the operator should be well trained, and the animal needs to be
anaesthetized, or else this simple operation could seriously hurt the animal, resulting in, for instance,
blindness [7,8]. Furthermore, it should be noted that anesthetics could alter the biochemical and
hematological composition [9]. For tail vein collection, the operator should also be well trained,
since some researchers just cut off the tail [10,11], which could seriously injure the animal, and the
blood might be obtained from both vein and artery. Among these methods, the blood collection
approaches-lateral saphenous vein/tail vein catheterization are relatively quick ways of collecting
blood from all strains of rodents. Furthermore, the animal does not need to be anesthetized, but just
needs slight restraining by hand. Thus, it is proposed that this is the best way of collecting multiple
blood samples.
The protein compositions in the blood serum hold a wealth of information about the health
status of patients. Furthermore, there is an increasing tendency towards studying the composition of
small molecules, such as metabolites, due to the fact that their levels can be significantly influenced
by many diseases, the administration of drugs, or by toxins [12,13]. Thus, blood measurements of
metabolites have a wide range of applications [14] using various technologies, such as proton nuclear
magnetic resonance spectroscopy (1H-NMR) [15], mass spectroscopy (MS) [16] and high-performance
liquid chromatography (HPLC) [17], etc. Among these methods, 1H-NMR is the most often utilized
to provide chemical and structural information of biological molecules [18] in a sample without any
damage. The 1H-NMR spectra of blood serum are dominated by broad resonances from proteins and
lipoproteins decorated by sharper resonances from small molecules. Aside from lipids, the dominant
small molecule in the 1H-NMR spectrum of serum/plasma is glucose [19]. Furthermore, a number of
amino acids and some organic acids are routinely detected, such as alanine, glutamine, leucine and
histidine, lactate, citrate and succinate, etc. Concentrations of these metabolites are influenced by the
brain state of the animal and the approach used of blood collection from the animal.
Thus, metabolomics studies of different blood collection approaches were investigated in the
current study, i.e., different bleeding sites: saphenous vein/tail vein/ITVC; different brain states:
awake/anesthesia; and different anesthetics: sevoflurane/pentobarbital. The chemical compositions of
the serum from these different kinds of approaches were compared. This study verified that acute
anesthesia could have an effect on blood compositions and that the bleeding site is also an influencing
factor, especially for ITVC. Furthermore, this study provided efficient and convenient approaches for
collecting multiple blood samples in a short period of time from awake animals.
2. Materials and Methods
2.1. Animals
The experimental protocols were approved by the animal care and use committee in Wuhan
Institute of Physics and Mathematics, the Chinese Academy of Sciences. All male rats (n = 9; 8 weeks
old) were ordered from VITAL RIVER (Beijing, China) and kept in SPF (Specific pathogen Free) animal
residence (Wuhan, China). Rats were housed in plastic cages in a climate-controlled room with 12 h
of light-dark illumination cycle at 25 ± 1 ◦C and relative 50 ± 10% humidity. During the experiment,
all rats were allowed free access to laboratory standard food and water. To minimize stress on the day
of the experiment, animals were weighed and handled daily for a week, including mildly touching the
skin/hair, catching the animal, and holding the animals in the hand for about one minute. Operations
of sample preparation can be found in the Supplementary Materials.
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2.2. Blood Collection
In order to compare the efficiency of blood collection methods from different bleeding sites,
the brain states, and the anesthetized states under different anesthetics, six groups of blood samples
were collected from the same animal: two from the saphenous vein under awake state (BSV0: n = 9;
BSV10: n = 8); three from the tail vein under awake (BTVA: n = 6) and different anesthesia states (BTVS: n
= 9 and pentobarbital-sample BTVP: n = 7); and the last one from the inferior thoracic vena cava (ITVC)
under anesthetized state (pentobarbital sodium, BITVC: n = 8). The whole experimental procedure
and operation methods are illustrated in Figure 1. One animal died during the anesthesia procedure,
and the blood collection operation was ceased after three attempts.
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collection from the saphenous vein and the tail vein under awake/anesthesia states (B). Note: B: blood;
SV0 or SV10: Blood collection from the saphenous vein after 0th or 10th day. T A, TVS or TVP: Blood
collection from the tail vein under awake or anesthesia state induced by sevoflurane or pentobarbital;
ITVC: Blo d collection from the inferior thoracic vena cava.
For saphenous vein (Blood sa ples: S 0 and BSV10): The rat was first restrained by hand, and
t e hair on he tarsal joint w s shaved. Then the hind limb was extended straight prior t blood
collection, a d the skin was smeared with V seline to avoi the blood spreading o to the skin and
to facilitate the f rmation of blood clots. Using a fi 23 G ne dle, the first puncture was performed
on the saphenous vein to collect the blood sample. Normally once is enough for blee ing, and he
puncture times should not exc d thre in one a tempt, in l ne with nimal care pr tocols. The bleeding
was stopped by pressin a gauze or tissue on the punctur site. The anim l was eturn to the home
c g after th bleeding was totally stanched. The steps of bl od collection are s ideo 1
(Sup lemental Materials).
For tail vein under awake state (Blo d sample: BTVA): plastic ani al holder and a specially
designed syringe were ne ded for this ap roach. The syringe (1 mL) was connected to a fine 23G
ne dle through a short length (~20 cm) of PE50 (O.D. 0.97 × I.D. 0.58 mm/L1.0m). At first, the awake
animal was restrained in the plastic animal holder. Then, the tail vein catheterization was completed in
the later l tai vein with the sp cial syringe (requiring more practice to achieve skilled operation) and
the sample (~200 µL) was collected by withdrawing the blood with the syringe. The steps of he blood
co lection are llust ated in Video 2 (Supplemental Materials).
For tail vein under anesthesia sta e (Blood samples: BTVS and BTVP): Two different anesthetics
were util zed in the current study: A: Sevoflurane (3–4%); B: 1% Pentobarbital (0.7 mL/10 g). In this
step, the rats did not ne d to be restrained by the animal holder, and the level of anesthesia was
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verified by the loss of righting reflex, such as lack of withdrawal response to a foot pinch. Blood
samples were directly collected from the lateral tail vein. The detailed steps are demonstrated in Video
3 (Supplemental Materials).
For ITVC (Blood sample: BITVC): At this point, a terminal procedure yielding maximal blood
volume was performed. After completing the blood collection from the lateral tail vein in the
anesthetized rat with pentobarbital, the rat chest was immediately opened to collect blood from the
ITVC. At the end, ~200 µL blood sample was collected for further analysis.
Detailed information about the materials, appliance, bleeding rates and blood volume for different
bleeding sites and brain states are illustrated in Table 1.
Table 1. The surgical materials for different kinds of blood sample collection approaches.
Bleeding Site Materials Appliance Animal State Bleeding Rate Blood Volume
Saphenous vein Needles (23G), Vaseline Electric shaver Awake 3.66 ± 0.72 µL/s ~400 µL
Tail vein Needles (23G), Syringe(1 mL), PE50 tubing
Rat holder,
Tweezer Awake 8.50 ± 1.70 µL/s ~400 µL
Tail vein
Needles (23G), Syringe
(1 mL), PE50 tubing
(0.058 cm × 0.097 cm)
Tweezer
Anesthetic
(sevoflurane/
pentobarbital
sodium)
8.50 ± 1.70 µL/s ~500 µL
Inferior thoracic
vena cava Syringe (2 mL) Scissor
Anesthetic
(pentobarbital
sodium)
~2 mL,
even more
2.3. Sample Preparation
The collected blood samples were immediately centrifuged at 6000× g for 10 min at 4 ◦C, and
the supernatant serum withdrawn by pipette and temporally stored on ice. After all the samples had
been collected, the ice-cold serum (50 µL) was transferred to a 5 mm NMR tube, and mixed with 50 µL
D2O (contained 5 mM formate) and 400 µL phosphate buffer (0.2 M Na2HPO4/NaH2PO4, pH 7.2).
The samples were uniformity mixed by vortex and kept at −20 ◦C for further NMR analysis.
2.4. H-NMR Detection
To detect the small molecular weight metabolites, 1H-NMR spectra of the serum samples were
obtained with Carr–Purcell–Meiboom–Gill (CPMG) pulse sequence in a Bruker AVANCE III 600 MHz
CryoProbes NMR spectrometer (Bruker, Rheinstetten, Germany). The acquisition parameters were
set as following: size of FID: 32 k; number of scans: 256; number of dummy scans: 4; spectral width:
20 ppm; 90◦ pulse length: 14.2 µs; spin-echo delay: 350 µs, number of loops: 80; and relaxation
delay: 3.4 s.
2.5. NMR Spectra Processing
All NMR spectral data were analyzed with the commercial software Topspin 2.1 (Bruker Biospin,
GmbH, Rheinstetten, Germany) and a home-made software NMRSpec [20] in MATLAB (R2018b,
Mathworks Inc. 2018,) (Freely available from the author upon request: jie.wang@wipm.ac.cn).
All the FID signals of 1H-NMR spectra were converted by adding the exponential window function
with a width increasing factor of 1Hz before the Fourier transformation (Topspin). Then the phase and
baseline correction were performed manually in Topspin, and the chemical signals were calibrated
with the inner standard-formate signal.
Furthermore, the NMR spectra data were imported to NMRSpec for peak alignment and integration.
Then, continuous even spectral bucketing (0.004 ppm) and the areas of the whole peaks [20] in all
spectra were automatically integrated in NMRSpec, and all bucketed spectra data and the peak areas
were normalized using the probabilistic quotient normalization (PQN) method which was implemented
in MATLAB [21] before comparing the total concentration differences.
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Due to the overlapped signals in the 1H-NMR spectra, the relative concentrations of these
metabolites were calculated based on the following procedures: the average chemical related peak
area in the NMR spectra of SSV0 samples was set as the reference ‘1’. The areas of the same peaks in all
samples were normalized using this reference, and the relative chemical concentration was calculated
by averaging the normalized peak areas in the same locations of the NMR spectra in the same group.
2.6. Statistical Analysis
In order to initially compare the differences of the metabolites in these different types of blood
collection approaches, the correlation of the metabolites in the NMR spectra were analyzed using the
PQN normalized areas of the peaks in the NMR spectra.
Then, the normalized data was imported into the SIMCA-p + software package (v11.0, Umetrics,
Malmö, Sweden) for multivariate statistical analysis. With the adoption of UV standardization of
pre-processing method, Principal component analysis (PCA) is mainly used for the observation of
sample clustering of the whole situation and the existence of outliers.
Then, the difference between these three different kinds of serum samples were analyzed with
the help of PLS-DA method (Partial Least Squares Discriminant Analysis). The PLS-DA method
is a classification algorithm based on partial least squares algorithm. Its function is to use the
mathematical model established by X to predict the classification of unknown samples in Y, at the same
time maximizing the separation of the two groups, which is helpful to find out the metabolites that
contribute to the classification. The significant varying metabolites were extracted from OPLS-DA
correlation coefficient color coded loading plots.
3. Results and Discussion
3.1. Blood Collection Methods
Many blood collection methods have been reported [5,22]. As stated in the introduction, most of
these methods have adverse effects such as tissue damage and contamination from the glands [8,23]
in awake animals. In order to avoid these problems, the animal could be anesthetized, which could
influence the metabolic components in the serum. Furthermore, most of these methods could not
be utilized with multiple sample collections from the same animal under an awake state. The
saphenous vein and tail vein blood collection methods have the minimum adverse effects on the
animals; this approach could be selected as the best representative of peripheral blood samples for
potential multiple samples collection in the same animal.
At first, three animals were appropriately anesthetized with sevoflurane during the second
blood collection. The rats showed a reduction in heart rate and blood pressure following sevoflurane
anesthesia. The blood vessels contracted and the rate of bleeding significantly decreased (almost no
bleeding) after puncture. Thus, the blood samples from the saphenous vein were only collected under
the awake state.
To demonstrate the effect of different brain states and body sites on the blood sampling procedure
in rats (n = 9), various blood collection methods were implemented under different conditions in the
current study, such as blood collections from different sites-saphenous vein/tail vein/ITVC, different
brain states-awake/anesthesia, different anesthetics-sevoflurane/pentobarbital.
3.2. Variation of 1H-NMR Spectra of Blood under Different Blood Collection Methods
An example of 1H–NMR spectra of the serum is shown in Figures 2A and 3-Blood. The peak
assignments and chemical shifts of the signals in 1H-NMR are illustrated in Table 2. The nuclear
magnetic signals of the metabolite were attributed to the laboratory data based on the two-dimensional
spectrum COSY, TOCSY, JRES, HSQC and HMBC, as well as the related literature [12,13,15,18,24–26]
and public databases (HMDB). These spectra mainly include the NMR signals of organic acid, amino
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fatty acid and creatinine as well as other metabolites such as choline metabolite ethanolamine purine
and pyrimidine metabolites.
Table 2. The NMR related information of the related proton signals in the small molecules in the
serum samples.
Metabolites Moieties 1H Shift(δ) Peak Num Structure
Lipid CH3 0.891(t) 1
CH3CH2CH2 1.210(m)
(CH2)n 1.221(m)
CH3CH2(CH2)n 1.232(m)
CH2 CH2CO 1.590(m)
CH2C=C 2.018(m)
CH2COO 2.238(m)
C=CCH2C=C 2.742(m)
C=CCH2C=C 2.749(m)
C=CCH2C=C 2.761(m)
Isoleucine δCH3 0.943(t) 2
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Table 2. Cont.
Metabolites Moieties 1H Shift(δ) Peak Num Structure
Acetate CH3 1.914(s) 12
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Table 2. Cont.
Metabolites Moieties 1H Shift(δ) Peak Num Structure
α-glucose H4 3.429(t) 35
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In order to evaluate the stability of these different blood collection methods, the average and the
standard error of the mean (SEM) of the 1H-NMR spectrum in every group were calculated point
by point after the spectral peak alignment was achieved (Figure 2B) [27]. The major metabolites
in the blood sample are more stable with the blood collection methods in the awake animal from
the saphenous vein (0 day-SSV0 or 10 days later-SSV10) or tail vein (STVs or STVA). The anesthesia
could contribute to the variation of the components especially for pentobarbital (STVP). Furthermore,
the bleeding site of ITVC could be used to obtain blood samples as often as necessary; however,
the metabolic components are too varied, especially for glucose (SITVC).
To initially evaluate the differences of the serum samples under various blood collection methods,
differences of the 1H-NMR spectra for blood samples under different conditions were calculated, and
are illustrated (Figure 3(A–F)), such as blood collection sites, brain states and anesthetics. This figure
shows the tendency of the small metabolites and lipids among different samples. The major metabolic
components in the blood sample are almost the same as those in the same brain state and blood
collection site in the close period (Figure 3(A), 10 days’ difference, except for lactate and lipids), even for
the different blood collection sites (Figure 3(B)). The anesthesia state could influence the compositions
of the blood samples (Figure 3(D,E)), and different anesthetics have different effects (Figure 3(F)).
The blood collection method from the ITVC had the most significant influence on the metabolites in
the blood sample, especially for glucose (Figure 3(C)). Without the involvement of standard deviation,
it was not possible to illustrate the statistical difference among the samples; thus, it was very important
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to do the statistical analysis in order to describe the difference and estimate the effect of anesthesia on
the blood composition.Molecules 2019, 24, x FOR PEER REVIEW 10 of 18 
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Figure 3. Differences of the average 1H–NMR spectra of blood samples from different approaches.
A) Difference in blood samples from the same blood collection site (saphenous vein) under awake
state in different periods (SSV0-SSV10); B): Effect of different blood collection sites under awake state
(SSV10-STVA); C): Effect of different blood collection sites in anesthesia state (STVP-SITVC); D): Effect
of sevoflurane on blood composition (SSV0-STVS); E): Effect of pentobarbital on blood composition
(SSV10-STVP); F): Effect of different anesthetics on blood compositions (STVS-STVP). Note: CS: chemical
shift.
3.3. Correlations of 1H-NMR Spectra of Blood Samples from Different Blood Collection Methods
To further explore the effects of different brain states, anesthetics and blood collection sites,
correlations of 1H-NMR spectra of different blood samples were compared. Here, the average PQN
normalized peak areas in the same group were utilized for calculation.
The correlations of various blood samples were calculated and illustrated (Figure 4A–F), such as
same site (different periods), different sites (Saphenous vein/tail vein in awake state or Tail vein/ITVC
in pentobarbital induced anesthesia state), awake and anesthesia state (sevoflurane/pentobarbital) or
different anesthetics (sevoflurane/pentobarbital).
Comparing the blood samples from the saphenous vein under awake state in different periods,
the major metabolic components of the blood samples were almost similar, except for lipids, which is
far from the central line (y = x, Figure 4A, r = 0.9884,). Furthermore, lipids are also the major different
component in different blood collection sites (saphenous vein vs. tail vein, Figure 4B) under awake
state, however, the other small metabolites were almost similar (R = 0.9555). It was more stable under
the anesthesia state induced by pentobarbital (Tail vein vs. ITVC, Figure 3(C)), especially for lipids.
Under different anesthetics, the major metabolic components were varied (Figure 3(D–F)), especially
for pentobarbital (R: 0.9087 for pentobarbital vs. 0.9549 for sevoflurane). Pentobarbital is a liquid
anesthetic; thus, it probably changes the components of the blood sample more significantly. In order
to check the contribution of the metabolites to the discrimination, further statistical analyses were
implemented in the next section.
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At the end, the first two components (PC1 and PC2) were calculated for six pairs of two different
kinds of samples, which are shown in Figure 6. The total contributions of the first two components
were higher than 50% of the variance of all variables and played major roles in the discrimination
analysis. The loading plots of PCA results indicated that there were no outliers among the serum
samples obtained from different approaches, as demonstrated by the clustering observed in the PCA
results (Figure 6A–E). There was a separation tendency for group discrimination in every comparison.
Thus, these preliminary results indicate that there could be some different metabolites in various blood
samples, even from the same site on different days.
Molecules 2019, 24, x FOR PEER REVIEW 13 of 18 
 
 
Figure 5. Loading plots of principal component analysis (PCA) of the NMR spectral data for all serum 
samples. Note: Every sample is represented by a unique pattern. 
 
Figure 6. Loading plots of principal component analysis (PCA) of the NMR spectral data from various 
blood samples. Note: Every sample is represented by a unique pattern. Note: A: BSV0 vs BSV10; B: BSV10 
vs BTVA; C: BIVP vs BITVC; D: BSV0 vs BTVS; E: BTVP vs BSV10; F: BTVS vs BTVP. 
3.5. OPLS-DA Analysis 
In order to specifically screen the different characteristics of serum collected using different 
methods, OPLS-DA models were constructed for further analysis. Parameters of R2X and Q2 are the 
main parameters for the model validation, R2X is used to explain the difference between the models, 
and Q2 reflects the ability of the prediction of the models. Results of R2X and Q2 for six different 
discriminate classification models are shown in Table 3, including the same bleeding site in different 
periods (SSV0 vs. SSV10), different bleeding sites under awake/anesthesia state (SSV10 vs. STVA and STVP vs. 
Figure 6. Loading plots of principal component anal i ) of the NMR spectral d ta from various
blood samples. Note: Every sa le is re resented by a unique pattern. Note: (A): SV0 vs. BSV10;
(B): BSV10 vs. BTVA; (C): BIVP vs. BITVC; (D): BSV0 vs. BTVS; (E): BTVP vs. BSV10; (F): BTVS vs. BTVP.
3.5. OPLS-DA Analysis
In order to specifically screen the different char t ri tics of serum collected using different
methods, OPLS-DA models were constructed for further analysis. Parameters of R2X and Q2 are the
main parameters for the model validation, R2X is used to explain the difference between the models,
and Q2 reflects the ability of the prediction of the models. Results of R2X and Q2 for six different
discriminate classification models are shown in Table 3, including the same bleeding site in different
periods (SSV0 vs. SSV10), different bleeding sites under awake/anesthesia state (SSV10 vs. STVA and STVP
vs. SITVC), different anesthesia states induced by sevoflurane/pentobarbital (SSV10 vs. STVS; SSV10 vs.
STVP and STVS vs. STVP).
Table 3. Statistical parameters of OPLS-DA analysis for different samples.
Statistical
Parameter
SSV0 vs.
SSV10
SSV10 vs.
STVA
STVP vs.
SITVC
SSV0 vs.
STVS
SSV10 vs.
STVP
STVS vs.
STVP
R2X 0.601 0.613 0.645 0.459 0.408 0.589
Q2 0.625 0.522 0.672 0.672 0.759 0.418
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The results of these six different pattern recognition analyses are represented as score scatter plots
(Figure 7A1–F1), which show the inherent clustering trends of the samples. The coefficient-coded
loading plots established by MATLAB script were employed to identify the significant contributing
metabolites among the serum samples from the saphenous vein and inferior thoracic vena cava
(Figure 7A2–F2).
The loading plots indicate that there were significant differences for the metabolites in these six
pairs of blood samples. For the awake state, the small molecules were almost similar from the same site
in different periods or different sites in the same periods. However, the lipids and lactate were different
in these two comparisons (Figure 7A2,B2). For the comparison of different bleeding sites under the
anesthesia state, the lipids are more stable, but the glucose was increased (Figure 7C2). Anesthetics
could change both small molecules and lipids (Figure 7D2,E2), such as increasing glucose, alanine,
glycerol and arginine, and decreasing lactate, lipid and glutamine, especially pentobarbital (Figure 7E2).
However, different anesthetics have different effects (Figure 7F2). Among these metabolites, it is
noticeable that the metabolites of glucose, lipid and lactic acid were the most significant components.
Thus, these metabolites were extracted for comparison in the next section.
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. . etabolites i iff i f l l
i to the results of OPLS-DA, the most significant different metabolites were lipids, lactate
and glucose. The relative concentratio s of these metabolites were calculated (Figure 8).
l l t i il i iti fr iff i l
i ( days’ difference). It was ignificantly increased under the anesthesia t te [28], even for a very
short period in the current study. Comparing both anesthetics, pentobarbital influe ced glucose m r
significantly, especially for the ITVC group, which might be caused by a longer time under anesthesia.
Former studies have shown that sevoflurane anesthesia could inhibit pancreaticβ-cells secreting insulin,
which may be caused by the continuous activation of adenosine triphosphate–sensitive potassium
channels in β-cells [29]. Insulin can induce the synthesis of glucokinase and promote glycolysis
in the liver. When the concentration of insulin decreases, the hepatic glucose homeostasis shifts
from glycogenolysis/gluconeogenesis to glycogen synthesis via insulin signaling, which increases the
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concentration of glucose in blood [29]. In the meanwhile, there is an extensive inhibition of substrate
oxidation in muscle mitochondria, which reduces glucose uptake. In fat tissue, a main effect of insulin
is the suppression of lipolysis and the reduced release of non-esterified fatty acids. In addition, lipolysis
and the concentration of fatty acid increase with the inhibition of insulin secretion.
Lipids and lactate were varied among different samples, even from the same site under different
periods or different sites on the same day. Thus, the influential factors could be very complicated for
these components, and it could be very difficult to verify the influence of a single factor in other studies.
The purpose of this study was to identify whether there was any difference in the samples obtained
using different sampling ways, such as the same bleeding site in different periods, different bleeding
site under awake/anesthesia state, or different anesthesia state induced by sevoflurane/pentobarbital.
Among these various samples, the ITVC group showed the most changes in metabolites, and probably
should not be used for the metabolic analysis in animal studies. Furthermore, Bernardi et al. also
found that the total leucocytes, absolute neutrophil and lymphocyte counts were significantly higher
in the samples collected from the peripheral sites than those samples collected from ITVC [30].
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3.7. Characteristics of Blood Collection Methods
Comparing these six different kinds of serum samples, the metabolites were varied, even from the
same method under different periods. Thus, we suggest that blood samples should be obtained on the
same day using the appropriate blood collection method.
Among various blood collection methods, the bleeding site from the saphenous vein is the most
convenient choice, even without any training. In the current study, there was no failed experiment;
however, the total blood volumes were varied at different times. For the tail vein, the operator should
be well trained, especially for awake animals. There was one failure in the anesthesia state (17 times in
total) and two in the awake state (8 times in total). However, more blood samples could be obtained
employing this method, even more than 0.5 mL per time, and the bleeding rate is much faster than
with the saphenous vein method. Both methods could be used for multiple blood collection. For the
method of ITVC, the terminal procedure yielded maximal blood volume; however, it was used only
once. Furthermore, the changes of the metabolites using this method should be considered, as the
blood components were different from the other site when the animal was under the same anesthesia
condition (BTVP vs. BITVC).
4. Conclusions
The current study compared the metabolites in blood samples using various blood collection
methods, including different bleeding sites, i.e., saphenous vein/tail vein/ITVC, awake/anesthetized
rats, and sevoflurane/pentobarbital induced anesthesia. The metabolic components in the blood were
influenced by the brain state of the animal, and anesthesia could significant increase the glucose
concentration and decrease the lactate concentrations, especially from ITVC. Therefore, the choice
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of the most suitable sampling site should be selected according to the experimental requirements.
From the perspective of animal welfare and multiple sampling, saphenous vein blood collection is
a simpler, more convenient and appropriate method. Furthermore, the tail vein blood collection
method is another suitable method for sufficient volume blood collection, but the operator needs to be
skilled. Both of these two methods are suitable for multiple blood collections, pharmacokinetics and
for studying the effects of drug interventions on animals.
Supplementary Materials: The following are available online. Video 1: Operations of blood collection from
saphenous vein; Video 2: Operations from tail vein under awake state; Video 3: Operations from tail vein under
anesthesia state.
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